The efficacy and safety of remimazolam and propofol in sedation endoscopic ultrasound: Multicenter, Random, Single blind, Prospective study

Hallym University Medical Center-Dongtan0 个研究点目标入组 400 人开始时间: 待定最近更新: 2022年9月20日

适应症

试验速览

暂无简介。

•1) Men or women between the ages of 20 and 70
•2) Subjects who have voluntarily decided to participate after hearing the explanation of the clinical trial process and signed the consent form
•3) All subjects requiring ultrasound endoscopy
•4) Subjects with class I or II in the American Society of Anesthesiology (ASA) risk assessment

•1) Pregnant woman
•2) Those who are susceptible to remimazolam, propofol or benzodiazepine drugs (midazolam), or those who are susceptible to eggs, beans, etc
•3) subjects undergoing adrenocortical or chronic steroid therapy or porphyria
•4) Subjects who are expected to have difficulty with airway intubation (subjects who have difficulty opening their mouths wide or have a thick neck and short neck)
•5) a subject diagnosed with sleep apnea
•6) Subjects with a history of reported risk cases during sedative endoscopy in the past
•7) Subjects with severe renal disease (serum creatinine >2 mg/dL)
•8) Subjects with severe heart disease (subjects with NYHA class III or IV)
•9) subjects who wish to receive an endoscopy without sincerity
•10) Subjects who cannot or are not willing to prepare an automatic test protocol or who do not agree to provide information;
•11) Subjects whose oxygen saturation is less than 90% or less than 95% despite the oxygen supply of 2 L/min
•12) Subjects with an underlying systolic blood pressure of less than 80 mmHg

发起方

Hallym University Medical Center-Dongtan